MUNICH, June 25, 2026 /PRNewswire/ — Innovative Molecules GmbH, a late-stage clinical biotechnology company focused on the development of differentiated antiviral therapies, today announced that the first patient has been dosed in its Phase 2a clinical trial evaluating…
News provided by PR Newswire.
